Literature DB >> 14695169

Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.

Sheila Seal1, Rita Barfoot, Hiran Jayatilake, Paula Smith, Anthony Renwick, Linda Bascombe, Lesley McGuffog, D Gareth Evans, Diana Eccles, Douglas F Easton, Michael R Stratton, Nazneen Rahman.   

Abstract

Fanconi Anemia (FA) is an autosomal recessive syndrome characterized by congenital abnormalities, progressive bone marrow failure, and susceptibility to cancer. FA has eight known complementation groups and is caused by mutations in at least seven genes. Biallelic BRCA2 mutations were shown recently to cause FA-D1. Monoallelic (heterozygous) BRCA2 mutations confer a high risk of breast cancer and are a major cause of familial breast cancer. To investigate whether heterozygous variants in other FA genes are high penetrance breast cancer susceptibility alleles, we screened germ-line DNA from 88 BRCA1/2-negative families, each with at least three cases of breast cancer, for mutations in FANCA, FANCC, FANCD2, FANCE, FANCF, and FANCG. Sixty-nine sequence variants were identified of which 25 were exonic. None of the exonic variants resulted in translational frameshifts or nonsense codons and 14 were polymorphisms documented previously. Of the remaining 11 exonic variants, 2 resulted in synonymous changes, and 7 were present in controls. Only 2 conservative missense variants, 1 in FANCA and 1 in FANCE, were each found in a single family and were not present in 300 controls. The results indicate that FA gene mutations, other than in BRCA2, are unlikely to be a frequent cause of highly penetrant breast cancer predisposition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695169

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Molecular cross-talk among chromosome fragility syndromes.

Authors:  Jordi Surrallés; Stephen P Jackson; Maria Jasin; Michael B Kastan; Stephen C West; Hans Joenje
Journal:  Genes Dev       Date:  2004-06-15       Impact factor: 11.361

2.  Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population.

Authors:  Nadhir Litim; Yvan Labrie; Sylvie Desjardins; Geneviève Ouellette; Karine Plourde; Pascal Belleau; Francine Durocher
Journal:  Mol Oncol       Date:  2012-09-11       Impact factor: 6.603

3.  Inflammatory ROS promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence.

Authors:  Xiaoling Zhang; Daniel P Sejas; Yuhui Qiu; David A Williams; Qishen Pang
Journal:  J Cell Sci       Date:  2007-04-03       Impact factor: 5.285

Review 4.  ATM and genome maintenance: defining its role in breast cancer susceptibility.

Authors:  Kum Kum Khanna; Georgia Chenevix-Trench
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-07       Impact factor: 2.673

Review 5.  Hereditary breast cancer: new genetic developments, new therapeutic avenues.

Authors:  Philippe M Campeau; William D Foulkes; Marc D Tischkowitz
Journal:  Hum Genet       Date:  2008-06-25       Impact factor: 4.132

6.  Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer.

Authors:  Marianne Berwick; Jaya M Satagopan; Leah Ben-Porat; Ann Carlson; Katherine Mah; Rashida Henry; Raffaella Diotti; Kelly Milton; Kanan Pujara; Tom Landers; Sat Dev Batish; José Morales; Detlev Schindler; Helmut Hanenberg; Robert Hromas; Orna Levran; Arleen D Auerbach
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

7.  Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.

Authors:  Minjie Wei; Jinhua Xu; James Dignam; Rita Nanda; Lise Sveen; James Fackenthal; Tatyana A Grushko; Olufunmilayo I Olopade
Journal:  Breast Cancer Res Treat       Date:  2007-10-12       Impact factor: 4.872

Review 8.  The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets.

Authors:  Maria José García; Javier Benítez
Journal:  Clin Transl Oncol       Date:  2008-02       Impact factor: 3.405

9.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

Authors:  Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

10.  BACH1 Ser919Pro variant and breast cancer risk.

Authors:  Pia Vahteristo; Kristiina Yliannala; Anitta Tamminen; Hannaleena Eerola; Carl Blomqvist; Heli Nevanlinna
Journal:  BMC Cancer       Date:  2006-01-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.